

News release

Kyowa Kirin Announces Update on Launch of Topical Ophthalmic Mitomycin C Agent and Antineoplastic Mitomycin C Agent Supply in Japan

Tokyo, Japan, July 18, 2023 --Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announced that the company will launch the topical ophthalmic mitomycin C agent (Mitomycin 2 mg for Ophthalmic Topical Use) and resume the supply of the antineoplastic mitomycin C agent (Mitomycin Injection 2 mg and Mitomycin Injection 10 mg) on July 27, 2023.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Reference

Kyowa Kirin Received Partial Change Approval of Antineoplastic Mitomycin C Agent in Japan (Press release, June 23, 2023)

https://www.kyowakirin.com/media_center/news_releases/2023/pdf/e20230623_01.pdf

Kyowa Kirin Announces Approval of Topical Ophthalmic Mitomycin C Agent in Japan (Press release, December 26, 2022)

https://www.kyowakirin.com/media_center/news_releases/2022/pdf/e20221226_01.pdf